middle.news
How Neurotech’s NTI164 Achieves Rapid Absorption with Minimal THC Exposure
11:45pm on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How Neurotech’s NTI164 Achieves Rapid Absorption with Minimal THC Exposure
11:45pm on Monday 2nd of June, 2025 AEST
Key Points
Rapid and predictable absorption of NTI164 with CBDA as dominant cannabinoid
Minimal THC exposure confirming non-intoxicating safety profile
No significant cannabinoid accumulation supporting twice-daily dosing
Stable CBDA to CBD ratio indicating targeted therapeutic action
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE